Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Ozempic stories

Nov 9, 2026

FDA requires GLP-1 drugmakers to add warning for rare eye condition

The FDA ordered makers of all GLP-1 medications, including Ozempic and Zepbound, to add label warnings about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss.

Nov 9, 2026·8 sources
00
Nov 6, 2026

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Nov 4, 2026

Novo Nordisk raises 2026 outlook for third time on strong Wegovy pill sales

Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.

Nov 4, 2026·4 sources
00
Oct 28, 2026

Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial

Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.

Oct 28, 2026·3 sources
00
Oct 26, 2026

Eli Lilly wins court ruling allowing weight-loss drug ads against Novo Nordisk

A US court denied Novo Nordisk's request to temporarily block Eli Lilly from using advertisements claiming its obesity drugs are more powerful, a setback for Novo as it battles to regain market share.

Oct 26, 2026·2 sources
00
Sep 9, 2026

Semaglutide linked to 40% reduction in asthma attacks in large real-world study

A large observational study found semaglutide (Ozempic/Wegovy) was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups compared to other treatments.

Sep 9, 2026·2 sources
00
Jul 14, 2026

Semaglutide may slow biological aging in adults with HIV

Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.

Jul 14, 2026·1 source
00
Jul 9, 2026

Dr. Reddy's Delays Generic Ozempic Launch Due to Ingredient Quality Issue

Indian drugmaker Dr. Reddy's Laboratories announced it is delaying commercial production of its generic semaglutide (Ozempic) after discovering an unspecified issue with the active pharmaceutical ingredient in some batches. Shares fell as much as 6.5%.

Jul 9, 2026·2 sources
00
May 3, 2026

Stopping and Restarting GLP-1 Weight Loss Drugs May Reduce Their Effectiveness

Preclinical study from University of Pennsylvania researchers finds that inconsistent use of GLP-1 medications like Ozempic and Wegovy may significantly lessen their effectiveness for weight loss.

May 3, 2026·1 source
00

GLP-1 Drugs Taken Around Pregnancy Show No Increased Risk of Birth Defects in New Study

University of St Andrews study published in American Journal of Obstetrics suggests weight-loss drugs like Ozempic taken around pregnancy do not raise the risk of major birth defects.

May 3, 2026·1 source
00
Apr 13, 2026

Genetic Variants Explain Why GLP-1 Drugs Like Ozempic Don't Work for 10% of Patients

New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.

Apr 13, 2026·1 source
00

Top claims

  • ▪The FDA required all GLP-1 drug manufacturers to add a nonarteritic anterior ischemic optic neuropathy safety warning to drug labels
  • ▪Cases of nonarteritic anterior ischemic optic neuropathy have been reported across all currently marketed GLP-1 medications, including semaglutide and tirzepatide products
  • ▪Nonarteritic anterior ischemic optic neuropathy is a rare eye condition caused by reduced blood flow to the optic nerve that can lead to sudden, permanent vision loss or blindness

Topics

Drug labeling & regulationDrug Policy, Pricing & ApprovalDrug safety & pharmacovigilanceGLP-1 medicationsEli LillyDrug safetyPost-market surveillanceGLP-1 receptor agonistsFDA regulationZepboundNovo NordiskGLP-1 drug side effectsFoundaoObesity treatmentRetatrutideDrug pricingGLP-1 / Weight-Loss MedicationsCompounding pharmaciesPrescription drug costsWeight loss medications & GLP-1 drugsPharmaceutical earningsPharmaceutical IndustryLifestyle, Wellness and NutritionWeight managementBlood sugar & insulinWeight loss drugsClinical trialsMarket competitionPharmaceutical marketingGLP-1Real world evidenceDrug Approval and Clinical TrialsSupplementationEvidence based supplementationRespiratory healthLongevity & agingMetabolic healthInfectious Disease and OutbreaksPublic healthcareGenetic drugsPregnancy & maternal healthPregnancy healthReproductive HealthWeight loss medicationsGLP-1 drugsSupplementation fundamentalsBiomarkers & bloodwork testingNutrition fundamentals

Related entities

TirzepatideSemaglutideWegovyHims & HersDenmarkCopenhagenUnited StatesTrentonIndiaMedication adherenceWeight lossGenetic